Lead Product(s) : ALC-079
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Linden Capital Partners
Deal Size : Undisclosed
Deal Type : Acquisition
Linden Capital Partners Acquires Alcresta Therapeutics, Inc.
Details : Alcresta Therapeutics has developed a novel enzyme-based (iLipase) platform, including ALC-079, which is being investigated for the Neonatal Intensive Care Unit for pancreatic immaturity.
Product Name : ALC-079
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : ALC-079
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Linden Capital Partners
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Acuitas
Deal Size : Undisclosed
Deal Type : Agreement
Details : As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver disease...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Acuitas
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ION455
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : AstraZeneca
Deal Size : $330.0 million
Deal Type : Licensing Agreement
Details : AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH).
Product Name : ION455
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : ION455
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : AstraZeneca
Deal Size : $330.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)
Details : The new publication details the potential for the development of EMM compositions that simultaneously target multiple biological pathways and address unmet needs in a range of complex diseases.
Product Name : AXA1125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2020
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Cambridge University
Deal Size : Inapplicable
Deal Type : Inapplicable
CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH
Details : The collaborative work uses CN Bio’s NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Cambridge University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXA1665
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data support AXA1665’s potential to address hyperammonemia, amino acid dysregulation and physical dysfunction in subjects with cirrhosis.
Product Name : AXA1665
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2020
Lead Product(s) : AXA1665
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks.
Product Name : AXA1125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2020
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : $110.0 million
Deal Type : Public Offering
Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange
Details : The expected IPO cash and its series D is earmarked for Poseida's leading candidate P-BCMA-101, an autologous CAR-T currently in a potentially registrational phase 2 trial for multiple myeloma.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : $110.0 million
Deal Type : Public Offering
Lead Product(s) : AXA1665
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results
Details : Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks.
Product Name : AXA1665
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : AXA1665
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXA1125,AXA1957
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD
Details : AXA1125-003 is a clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver in adult with nonalcoholic fatty liver disease.
Product Name : AXA1125
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2020
Lead Product(s) : AXA1125,AXA1957
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable